These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31390548)

  • 41. Metabolic Control of CD8
    Zhang L; Romero P
    Trends Mol Med; 2018 Jan; 24(1):30-48. PubMed ID: 29246759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor Cholesterol Up, T Cells Down.
    Picarda E; Ren X; Zang X
    Cell Metab; 2019 Jul; 30(1):12-13. PubMed ID: 31269422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells.
    Zhao K; Zhou Y; Qiao C; Ni T; Li Z; Wang X; Guo Q; Lu N; Wei L
    J Hematol Oncol; 2015 Apr; 8():41. PubMed ID: 25902914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Emerging Role of CD8
    Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
    Front Immunol; 2018; 9():1904. PubMed ID: 30158938
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early changes in the metabolic profile of activated CD8(+) T cells.
    Cammann C; Rath A; Reichl U; Lingel H; Brunner-Weinzierl M; Simeoni L; Schraven B; Lindquist JA
    BMC Cell Biol; 2016 Jul; 17(1):28. PubMed ID: 27387758
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
    Jiang Z; Liu Z; Li M; Chen C; Wang X
    EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic reprogramming of human CD8
    Jeng MY; Hull PA; Fei M; Kwon HS; Tsou CL; Kasler H; Ng CP; Gordon DE; Johnson J; Krogan N; Verdin E; Ott M
    J Exp Med; 2018 Jan; 215(1):51-62. PubMed ID: 29191913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-194 regulated AGK and inhibited cell proliferation of oral squamous cell carcinoma by reducing PI3K-Akt-FoxO3a signaling.
    Chi H
    Biomed Pharmacother; 2015 Apr; 71():53-7. PubMed ID: 25960215
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia.
    Sun K; Zhang Y; D'Alessandro A; Nemkov T; Song A; Wu H; Liu H; Adebiyi M; Huang A; Wen YE; Bogdanov MV; Vila A; O'Brien J; Kellems RE; Dowhan W; Subudhi AW; Jameson-Van Houten S; Julian CG; Lovering AT; Safo M; Hansen KC; Roach RC; Xia Y
    Nat Commun; 2016 Jul; 7():12086. PubMed ID: 27417539
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
    André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
    Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.
    Yuling H; Ruijing X; Li L; Xiang J; Rui Z; Yujuan W; Lijun Z; Chunxian D; Xinti T; Wei X; Lang C; Yanping J; Tao X; Mengjun W; Jie X; Youxin J; Jinquan T
    Cancer Res; 2009 Oct; 69(20):7935-44. PubMed ID: 19808969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
    Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
    Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
    Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E
    Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8
    Choi BK; Lee DY; Lee DG; Kim YH; Kim SH; Oh HS; Han C; Kwon BS
    Cell Mol Immunol; 2017 Sep; 14(9):748-757. PubMed ID: 26972770
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.